H. Hoogendoorn

发表

Protamine requirements in cardiac surgery: effect of changes in the heparin reference standard.

L. Stitt, Anthony K. C. Chan, L. Berry, 2014, Journal of cardiothoracic and vascular anesthesia.

In vivo studies of the role of factor VII in hemostasis.

A. Giles, S. Tinlin, H. Hoogendoorn, 1985, Blood.

Alpha 2-macroglobulin binds and inhibits activated protein C.

A. Giles, C. Toh, M. Nesheim, 1991, Blood.

Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C.

A. Giles, F. Taylor, A. Chang, 1992, Blood.

Type IIB von Willebrand's disease presenting as thrombocytopenia during pregnancy

A. Giles, H. Hoogendoorn, K. Benford, 1987, British journal of haematology.

Uptake of heparin cofactor II and antithrombin into the aorta wall after a deendothelializing injury in vivo: comparison with the behaviors of prothrombin and fibrinogen.

M. Blajchman, M. Richardson, H. Hoogendoorn, 1999, The Journal of laboratory and clinical medicine.

Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics

J. Kirklin, W. Holman, H. Hoogendoorn, 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency.

A. Giles, M. Andrew, L. Mitchell, 1994, Blood.

Monoclonal antibodies against Epstein–Barr virus cross-react with α-synuclein in human brain

M. Tarnopolsky, J. Woulfe, H. Hoogendoorn, 2000, Neurology.

Monoclonal antibodies against Epstein-Barr virus cross-react with alpha-synuclein in human brain.

M. Tarnopolsky, D. Munoz, J. Woulfe, 2000, Neurology.

Absence of elevated anti–&agr;-synuclein and anti-EBV latent membrane protein antibodies in PD

E. Masliah, J. Langston, D. D. Di Monte, 2002, Neurology.

The generation of thrombin in vivo induces the selective loss of high molecular weight multimers of von Willebrand factor and the reversible sequestration of platelets

A. Giles, C. Toh, H. Hoogendoorn, 1993, British journal of haematology.

A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model.

A. Giles, M. Nesheim, H. Hoogendoorn, 1990, Blood.

Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography.

J. Hirsh, M. Blajchman, F. Ofosu, 1980, Thrombosis research.

The Fibrinolytic Potential of the Normal Primate following the Generation of Thrombin In Vivo

A. Giles, M. Nesheim, D. Stump, 1990, Thrombosis and Haemostasis.

A reproducible model for the study of factor X kinetics in AA amyloidosis.

A. Giles, R. Kisilevsky, L. Boudreau, 1988, Experimental and molecular pathology.

In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency).

A. Giles, S. Tinlin, N. Pancham, 1988, Blood.

Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency)

A. Giles, S. Tinlin, P. Greenwood, 1984 .

The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits.

K. Mann, A. Giles, M. Nesheim, 1982, Blood.

The thrombogenicity of prothrombin complex concentrates: III. The relationship of in vivo thrombogenicity to the nature of the starting plasma.

A. Giles, M. Blajchman, H. Hoogendoorn, 1981, Thrombosis Research.

The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits.

J. Hirsh, A. Giles, M. Blajchman, 1980, Thrombosis research.

The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits.

J. Hirsh, A. Giles, M. Blajchman, 1980, Thrombosis Research.

Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus.

E. Silverman, C. Male, L. Mitchell, 2005, Blood.

The thrombogenicity of prothrombin complex concentrates. IV. The source of coagulant-active phospholipid.

A. Giles, S. Tinlin, H. Hoogendoorn, 1984, Thrombosis research.

Stroma free human platelet lysates potentiate the in vivo thrombogenicity of factor Xa by the provision of coagulant‐active phospholipid

K. Mann, A. Giles, M. Nesheim, 1982, British journal of haematology.

In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency).

A. Giles, S. Tinlin, N. Pancham, 1988, Blood.

vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in The coagulant-active phospholipid content is a major determinant of in

A. Giles, H. Hoogendoorn, P. Tracy, 2011 .

Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C‐deficient family

F. Rosendaal, P. Callas, K. Bauer, 2004, Journal of thrombosis and haemostasis : JTH.

Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.

K. Mann, A. Giles, G. Rivard, 1984, The Journal of clinical investigation.

Activation of Protein C and Its Distribution between Its Inhibitors, Protein C Inhibitor, α1-Antitrypsin and α2-Macroglobulin, in Patients with Disseminated intravascular Coagulation

M. Scully, M. Nesheim, H. Hoogendoorn, 1993, Thrombosis and Haemostasis.

Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits.

M. Blajchman, H. Hoogendoorn, M. Hatton, 1997, The American journal of physiology.

Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency).

A. Giles, S. Tinlin, P. Greenwood, 1984, Blood.

VIII : C deficiency ) Development of factor VIII : C antibodies in dogs with hemophilia A ( factor

S. Tinlin, P. Greenwood, H. Hoogendoorn, 2005 .